跳至主要内容
临床试验/NL-OMON31474
NL-OMON31474已完成2 期

Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination - Optimal frequency of Avastin injections in ARMD.

Oogziekenhuis Rotterdam0 个研究点目标入组 360 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Informed consent
  • - Endophthalmitis risks have been made clear
  • - No preference to paritcipate in the Infliximab for ARMD trial
  • - Age >= 65 years
  • - Exudative subfoveolar age related macular degeneration
  • - No significant other ocular disorders affecting visual acuity
  • - Not immunocompromised
  • - No allergy for fluorescein or ICG dye injections
  • - No treatment for ARMD or other retinal problem in the 3 months prior to trial start
  • - No planned ocular surgery in the first year after trial start

排除标准

  • - Use of coumarin-derivatives at the time of inclusion
  • - Clinical significant CVA or MCI in the 6 months prior to planned inclusion

研究者

发起方
Oogziekenhuis Rotterdam

相似试验